GlassScriptPhysician profile
April Shih Wu
NPI 1902496789
$2,535.77
in general payments reported to CMS, 2019-2025
32 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $235 · 2022: $680 · 2023: $427 · 2024: $643 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.16 |
| Education | $109.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $424.47 | 2021-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $310.60 | 2023-2025 | Verzenio, Jaypirca |
| Glaxosmithkline, LLC. | $235.84 | 2022-2025 | Ojjaara |
| Regeneron Healthcare Solutions, INC. | $160.33 | 2024-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $141.37 | 2023-2025 | |
| Celgene Corporation | $137.01 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $134.04 | 2021-2025 | Ninlaro, Iclusig |
| Janssen Biotech, INC. | $113.46 | 2021-2025 | Carvykti, Rybrevant, Talvey |
| Seagen INC. | $107.08 | 2021-2023 | Tukysa |
| Scynexis, INC. | $89.91 | 2022 | |
| Daiichi Sankyo INC. | $66.95 | 2024 | Enhertu |
| Genentech USA, INC. | $63.05 | 2023-2025 | Itovebi, Tecentriq, Lunsumio |
| Astrazeneca Pharmaceuticals LP | $60.65 | 2021-2025 | Enhertu |
| Adc Therapeutics America, INC. | $46.11 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $39.64 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $37.96 | 2021-2025 | Zoladex |
| Rigel Pharmaceuticals, INC. | $36.88 | 2022-2024 | Rezlidhia, Tavalisse |
| Kite Pharma, INC. | $32.36 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $32.09 | 2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $30.48 | 2022 | |
| Amgen INC. | $29.83 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.78 | 2022 | |
| Abbvie INC. | $21.96 | 2025 | |
| Merck Sharp & Dohme LLC | $20.93 | 2022 | |
| Acrotech Biopharma INC. | $20.23 | 2025 | Beleodaq |
| Deciphera Pharmaceuticals INC. | $19.08 | 2025 | Romvimza, Qinlock |
| Caris Mpi, INC. | $18.22 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $18.07 | 2022 | |
| Iovance Biotherapeutics, INC. | $17.15 | 2025 | Amtagvi |
| Janssen Pharmaceuticals, INC | $15.99 | 2025 | |
| Pharmacosmos Therapeutics INC. | $15.54 | 2024 | Cosela |
| Kyowa Kirin, INC. | $14.71 | 2023 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.